
    
      This is an open-label extension study of plecanatide in the treatment of patients with CIC
      who previously completed Synergy Protocols SP304-20210 and SP304203-00 (The CIC3 Study).

      The planned duration of each patient's study participation is up to 411 days, including up to
      33 days of screening, 8 study visits over 52 weeks of treatment and a follow-up visit 2 weeks
      after the last dose of study drug.
    
  